Table 1.
Vaccines under development based on Protein Subunit for COVID-19 according to the WHO as of April 20, 2020 (adapted from (20).
| platform | developer | Phase of study | |
|---|---|---|---|
| Protein Subunit | Drosophila S2 insect cell expression system VLPs | ExpreS2ion | preclinical |
| Protein Subunit | S protein | WRAIR/USAMRIID | preclinical |
| Protein Subunit | S-Trimer | Clover Biopharmaceuticals Inc./GSK | preclinical |
| Protein Subunit | Peptide | Vaxil Bio | preclinical |
| Protein Subunit | S protein | AJ Vaccines | preclinical |
| Protein Subunit | Ii-Key peptide | Generex/EpiVax | preclinical |
| Protein Subunit | S protein | EpiVax/Univ. of Georgia | Preclinical |
| Protein Subunit | S protein (baculovirus production) | Sanofi Pasteur | Preclinical |
| Protein Subunit | Full length S trimers/ nanoparticle + Matrix M | Novavax | Preclinical |
| Protein Subunit | gp-96 backbone | Heat Biologics/Univ. Of Miami | Preclinical |
| Protein Subunit | Molecular clamp stabilized Spike protein | University of Queensland/GSK | Preclinical |
| Protein Subunit | S1 or RBD protein | Baylor College of Medicine | Preclinical |
| Subunit | Subunit protein, plant produced | iBio/CC-Pharming | Preclinical |
| Protein Subunit | Subunit | VIDO-InterVac, University of Saskatchewan | Preclinical |
| Protein Subunit | Adjuvanted microsphere peptide | University of Saskatchewan | Preclinical |
| Protein Subunit | Full-length Spike, S1, RDB, nucleocapsid Formulated with adjuvants /or fused with Fc |
(Novavax, Phase III) recombinant S protein (Vaxine Pty Ltd, Australia, Phase I) | Preclinical |
| Protein Subunit | S protein (adenovirus production | Johnson & Johnson (Jansen): In partnership with Biomedical Advanced Research and Development Authority (BARDA) | Preclinical |